<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275376</url>
  </required_header>
  <id_info>
    <org_study_id>CF16263B</org_study_id>
    <nct_id>NCT03275376</nct_id>
  </id_info>
  <brief_title>Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Target therapy with sorafenib is the standard of treatment for advanced Hepatocellular&#xD;
      carcinoma (HCC), but the patient survival time is still unsatisfactory. The aims of this&#xD;
      study are to prove statins improve the tumor responses and overall survival for patients who&#xD;
      receive sorafenib therapy for advanced HCC by a prospective randomized controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,&#xD;
      including the condition in Taiwan, and the management of HCC is an important challenge in&#xD;
      public health. Target therapy with sorafenib is the standard of treatment for advanced HCC&#xD;
      (vascular invasion or extrahepatic metastasis), but the patient survival time is still&#xD;
      unsatisfactory. In recent years, growing evidences, including mechanism analysis, have&#xD;
      suggested the anitneoplastic effects of statin, and a recent pooled analysis found that&#xD;
      statin use may be associated with improved survival in patients with metastatic rencal cell&#xD;
      carcinoma. However, a prospective clinical trial of statin sorafenib combination therapy in&#xD;
      the treatment of advanced HCC is lacking.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        1. To prove statins improve the overall survival for patients who receive sorafenib therapy&#xD;
           for advanced HCC by a prospective randomized controlled study.&#xD;
&#xD;
        2. To prove statin can improve tumor responses and the progression free survival for&#xD;
           patients who receive sorafenib therapy for advanced HCC by a prospective randomized&#xD;
           controlled study.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This randomized placebo-controlled study will prospectively enroll patients who receiving&#xD;
      sorafenib therapy for advanced HCC in the Taichung Veterans General Hospital, and statin or&#xD;
      placebo will be statin or placebo will be administered according to randomized allocations.&#xD;
      Tumor responses, time to tumor progression, and survival time will be followed and recorded&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow in patient enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">March 13, 2021</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Three year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best tumor response</measure>
    <time_frame>Three year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Three year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Overall Survival</condition>
  <condition>Tumor Responses</condition>
  <arm_group>
    <arm_group_label>Statin treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10mg</intervention_name>
    <description>Atorvastatin or placebo will be administered according to randomized allocations.</description>
    <arm_group_label>Statin treated group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Atorvastatin or placebo will be administered according to randomized allocations.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients more than 40 years old&#xD;
&#xD;
          2. HCCs diagnosed by AASLD image criteria or pathology&#xD;
&#xD;
          3. HCCs in BCLC advanced stage, with portal vein thrombosis (VP3 or VP4) or extrahepatic&#xD;
             metastasis&#xD;
&#xD;
          4. Not suitable or failed to locoreginal treatments for HCC&#xD;
&#xD;
          5. Child-Pugh score = or &lt; 6&#xD;
&#xD;
          6. ECOG performance status (PST) 0-2&#xD;
&#xD;
          7. Serum bilirubin &lt; 2 mg/dL and prothrombin time (PT) prolongation &lt; 3 seconds&#xD;
&#xD;
          8. Will receive sorafenib therapy&#xD;
&#xD;
          9. Life expectancy &gt; 3 months&#xD;
&#xD;
         10. Will follow the pregnancy prevention protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HCC is considered for curative therapy&#xD;
&#xD;
          2. HCC with brain metastasis&#xD;
&#xD;
          3. History of systemic therapy for HCC&#xD;
&#xD;
          4. Indications for statin use, such as hyperlipidemia in cardiovascular diseases&#xD;
&#xD;
          5. Any local treatment for HCC within 4 weeks&#xD;
&#xD;
          6. Any active gastrointestinal bleeding within 4 weeks&#xD;
&#xD;
          7. Liver transplant history or concomitant immunosuppressive therapy&#xD;
&#xD;
          8. Concurrent any other malignancy&#xD;
&#xD;
          9. Allergy to sorafenib or statins&#xD;
&#xD;
         10. Pregnancy or lactation&#xD;
&#xD;
         11. Serum AST or ALT &gt; 5x upper limit of normal&#xD;
&#xD;
         12. Known HIV infection&#xD;
&#xD;
         13. eGFR &lt; 30 ml/min&#xD;
&#xD;
         14. Abnormal medical conditions that are unsuitable for study, such as uncontrolled&#xD;
             hypertension, coronary arterial disease, or arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teng-Yu Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. 2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 3. Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015;33:172-179. 4. Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516. 5. Singh S, Singh PP, Roberts LR, et al. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2014;11:45-54. 6. Demierre MF, Higgins PD, Gruber SB, et al. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942. 7. Wu J, Wong WW, Khosravi F, et al. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-6468. 8. Rao S, Porter DC, Chen X, et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A 1999;96:7797-7802. 9. El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009;136:1601-1608. 10. Tsan YT, Lee CH, Wang JD, et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623-630. 11. Chiu HF, Ho SC, Chen CC, et al. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106:894-898.</citation>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Teng-Yu Lee</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

